Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2018–2022

ELBA · European Liquid Biopsies Academy - Towards widespread clinical application of blood- based diagnostic tools

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2018-01-01 → 2022-09-30
Финансиране от ЕС
3 727 723 €
Участници
21
Схема
MSCA-ITN

Линиите свързват координатора с партньорите.

Накратко на български

Тестовете за „течна биопсия“ анализират кръвта за откриване на рак на белия дроб и избор на подходяща терапия. Тези методи са по-безопасни и по-лесни от традиционните тъканни биопсии, което помага за по-бързото им приложение в медицината.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

European Liquid Biopsies Academy - Towards widespread clinical application of blood-based diagnostic tools

Liquid biopsies have been heralded as a game-changer in cancer management, with blood tests offering a minimally invasive, safe, and sensitive alternative or complementary approach for tissue biopsies. Blood represents a rich source of information through which solid cancers (and their subtypes) can be detected, identified and classified, and matched to a specific therapy. However, despite the potential of individual approaches, the promise of liquid biopsies has not yet materialized in the clinic. Widespread deployment requires creative next-generation researchers with an innovative mind-set with access to a unique toolbox, including medical know-how, molecular diagnostics expertise (from health economics to regulatory), and statistical/bioinformatics proficiency. Currently, there are no comprehensive training programs to address this need. To move the promising liquid biopsy technology out of its infancy, the research program and educational curriculum of the European Liquid Biopsy Academy (ELBA) covers the entire value chain of diagnostics development and integrates all required disciplines and sectors. ELBA educates 15 Early Stage Researchers (ESRs) with the skills to circumvent the obstacles currently hampering effective development and commercialization of liquid biopsy approaches. By creating a sustainable network to foster long-term multidisciplinary relationships and communication networks with various stakeholders we aim to accelerate clinical translation of these blood-based diagnostics. ELBA focuses on the development of blood tests for early lung cancer detection and therapy selection.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Liquid biopsies have been heralded as a game changer in cancer management, with blood tests offering a minimally invasive, safe, and sensitive alternative or complimentary approach for tissue biopsies. Blood represents a rich source of information through which solid cancers (and their subtypes) can be detected, identified and classified, and matched to a specific therapy. However, despite the potential of individual approaches, the promise of liquid biopsies has not yet materialised in the clinic. Widespread deployment requires creative next-generation researchers with an innovative mindset with access to a unique toolbox, including medical know-how, molecular diagnostics expertise (from health economics to regulatory), and statistical/bioinformatical proficiency. Currently, there are no comprehensive training programmes to address this need. To move the promising liquid biopsy technology out of its infancy, the research programme and educational curriculum of the European Liquid Biopsy Academy (ELBA) will cover the entire value chain of diagnostics development and integrate all required disciplines and sectors. ELBA will educate 15 Early Stage Researchers (ESRs) with the skills to circumvent the obstacles currently hampering effective development and commercialisation of liquid biopsy approaches. By creating a sustainable network to foster long-term multidisciplinary relationships and communication networks with various stakeholders we aim to accelerate clinical translation of these blood-based diagnostics. Most importantly, we have designed a well-balanced training programme to provide excellent career opportunities for the 15 ELBA ESRs. this includes training on state-of-the-art technologies and tools; bioinformatics, biostatistics and mathematical modelling; health economics and health technology assessment; diagnostic test development (including intellectual property and regulatory affairs); transferable skills (including leadership) and patient inclusion.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз